Adovate Closes $6 Million Round Oversubscribed
Adovate is pleased to announce that it has successfully closed and oversubscribed its $6 million Convertible Note financing round. The strong interest in this round reflects continued support for our focused approach to developing next-generation adenosine-based small molecules to address serious unmet clinical needs.
This financing is designed to allow Adovate to capitalize on its recent progress, including continuation of our first-in-man study of ADO-5030, our lead drug candidate for asthma; acceptance into the Johnson & Johnson JLABS innovation program, which fosters scientific discovery and accelerates the development of transformative healthcare solutions; and building of our patent portfolio around ADO-5030 and other pipeline products with additional patent issuances.
With this funding, Adovate is now positioned to:
- Complete the Phase 1 clinical/human study of ADO-5030.
- Proceed with a proof-of-concept to study of ADO-5030 in humans as a treatment for asthma.
- Broaden our drug development pipeline across additional indications.
- Explore strategic partnerships to support continued development and potential commercialization of ADO-5030.